Biologics vs JAK Inhibitors — Clinical Trial Comparison
Biologics
Large-molecule proteins targeting specific cytokines or receptors
VS
JAK Inhibitors
Oral small molecules blocking intracellular inflammatory signalling
Biologics and JAK inhibitors are two of the most important treatment classes for autoimmune and inflammatory diseases. Both target the immune system but through entirely different mechanisms — biologics intercept inflammatory signals outside the cell, while JAK inhibitors block the intracellular signalling pathways that those signals activate. Understanding their trial profiles can help you find the right study for your condition.
Key Differences at a Glance
| Feature | Biologics | JAK Inhibitors |
|---|---|---|
| Mechanism | Large protein molecules (antibodies, fusion proteins) that bind and neutralise specific cytokines (TNF, IL-6, IL-17, IL-23) or cell-surface receptors outside the cell | Small-molecule drugs that enter cells and block Janus kinase (JAK) enzymes, preventing cytokine signal transduction inside the cell |
| Route of administration | Subcutaneous injection or intravenous infusion (cannot be taken orally — proteins are digested) | Oral tablets — taken by mouth once or twice daily |
| Selectivity | Target one specific cytokine or receptor (e.g., TNF only, IL-6 only) | Block multiple cytokine pathways simultaneously (JAK-STAT signals from IL-6, IFN, IL-12, IL-23 and others) |
| Examples in trials | Infliximab, adalimumab, etanercept, ustekinumab, secukinumab, tocilizumab, natalizumab | Tofacitinib, baricitinib, upadacitinib, filgotinib, abrocitinib, ruxolitinib |
| Time to effect | 2–12 weeks for full response | 1–4 weeks (generally faster onset) |
| Immunogenicity risk | Can develop anti-drug antibodies that reduce efficacy over time | No anti-drug antibodies (small molecules are not immunogenic) |
Clinical Trial Availability
| Trial Aspect | Biologics | JAK Inhibitors |
|---|---|---|
| UK trials actively recruiting | 150–250 studies | 80–150 studies |
| Most common phases | Phase 2–4 (many biosimilar Phase 3) | Phase 2–3 (expanding into new indications) |
| Top conditions studied | Rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, lupus, asthma, COPD, MS | Rheumatoid arthritis, psoriasis, eczema, ulcerative colitis, Crohn's disease, alopecia, vitiligo, myelofibrosis |
| Combination trials | Biologic + MTX, biologic + biologic (rare), biologic + small molecule | JAKi + topical, JAKi + biologic (emerging), JAKi monotherapy vs combo |
| Paediatric trials | Extensive — many approved for children (JIA, paediatric IBD) | Growing — some approved for adolescents, more paediatric trials opening |
| Biosimilar/generic activity | Heavy biosimilar trial activity (infliximab, adalimumab biosimilars) | Not yet — JAK inhibitors still under patent; first generics expected late 2020s |
Exciting Emerging Treatments
Biologics Trials
- Bispecific antibodies — targeting two cytokines simultaneously for dual pathway blockade
- Longer-acting formulations — extending dosing intervals to every 8–12 weeks
- Oral biologics — developing biologic molecules that survive oral administration
- Biosimilar switching studies — testing safe switching between originator and biosimilar
- Tissue-targeted biologics — gut-selective, lung-selective approaches to reduce systemic exposure
- Biologic withdrawal/remission studies — testing whether treatment can be stopped after remission
JAK Inhibitor Trials
- Selective JAK inhibitors — targeting JAK1 only (upadacitinib) to reduce side effects of pan-JAK blockade
- Topical JAK inhibitors — ruxolitinib cream for eczema and vitiligo without systemic exposure
- Neuroinflammation — testing JAK inhibitors in multiple sclerosis and neurodegenerative conditions
- Interstitial lung disease — JAK inhibition for fibrotic lung conditions
- Combination with biologics — dual immunomodulation for refractory disease
- Prevention trials — using JAK inhibitors to prevent disease onset in at-risk populations
💡 Not sure which trials you qualify for?
Use our Smart Matcher to answer a few questions about your condition and we'll find the most relevant trials for your specific situation — free, instant results.
Eligibility Differences
Biologics Trial Criteria
- Confirmed diagnosis with inadequate response or intolerance to conventional therapy (often DMARDs for RA)
- No active infection (TB screening required — biologic treatment can reactivate latent TB)
- No active hepatitis B or C (some trials allow with antiviral prophylaxis)
- Adequate blood counts and organ function
- Washout period from prior biologic (typically 4–12 weeks depending on drug half-life)
- No live vaccines within 4 weeks before enrolment
JAK Inhibitor Trial Criteria
- Confirmed diagnosis — some trials accept DMARD-naive patients, others require prior biologic failure
- No active serious infections (similar infection screening as biologics)
- Adequate haematological parameters (JAK inhibitors can affect blood counts)
- No history of venous thromboembolism (VTE risk is a key concern for some JAK inhibitors)
- Lipid monitoring (JAK inhibitors can raise cholesterol)
JAK Inhibitor Trials
Browse JAK inhibitor trials for autoimmune and inflammatory conditions
JAK Inhibitor TrialsFrequently Asked Questions
Can I switch from a biologic to a JAK inhibitor (or vice versa)?
Yes — switching between biologics and JAK inhibitors is common clinical practice when the first treatment doesn't work or stops working. Many clinical trials specifically recruit patients who have failed one class to test the other. Your rheumatologist or gastroenterologist can advise on the best sequencing for your condition.
Are JAK inhibitors safer than biologics?
Neither class is universally safer — they have different risk profiles. Biologics carry risks of infusion reactions, injection site reactions, and specific infections (TB reactivation, fungal infections). JAK inhibitors carry boxed warnings for serious infections, blood clots, and certain cancers based on post-marketing data. Both require regular monitoring.
Why would a trial choose a JAK inhibitor over a biologic?
JAK inhibitors offer oral administration (tablets) rather than injections or infusions, which many patients prefer. They also work on multiple cytokine pathways simultaneously, potentially offering broader efficacy. Trials may test JAK inhibitors when biologics have failed, or as first-line alternatives comparing convenience and outcomes.